Definitive Healthcare (DH)
(Delayed Data from NSDQ)
$4.34 USD
+0.28 (6.90%)
Updated Aug 21, 2024 04:00 PM ET
After-Market: $4.34 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.34 USD
+0.28 (6.90%)
Updated Aug 21, 2024 04:00 PM ET
After-Market: $4.34 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth F Momentum B VGM
Zacks News
Definitive Healthcare Corp. (DH) Meets Q2 Earnings Estimates
by Zacks Equity Research
Definitive Healthcare (DH) delivered earnings and revenue surprises of 0% and 0.56%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
DH or PRVA: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
DH vs. PRVA: Which Stock Is the Better Value Option?
Bears are Losing Control Over Definitive Healthcare (DH), Here's Why It's a 'Buy' Now
by Zacks Equity Research
Definitive Healthcare (DH) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
5 Medical Info Systems Stocks to Buy for Stable Returns
by Nalak Das
We have narrowed our search to five medical info systems stocks that have strong growth potential for 2024. These stocks are: HIMS, BFLY, ENOV, LUNG, DH.
Definitive Healthcare Corp. (DH) Matches Q1 Earnings Estimates
by Zacks Equity Research
Definitive Healthcare (DH) delivered earnings and revenue surprises of 0% and 0.81%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Definitive Healthcare Corp. (DH) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Definitive Healthcare Corp. (DH), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Definitive Healthcare Corp. (DH) Soars 7.1%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Definitive Healthcare Corp. (DH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Alcon (ALC) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Alcon (ALC) might have benefitted from the high win rate of Argos Biometer in the second quarter.
3 Medical Product Stocks Set to Outpace Q2 Earnings Estimates
by Indrajit Bandyopadhyay
Medical Product companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how NEOG, PDCO and DH are poised ahead of their earnings release.
Zymeworks Inc. (ZYME) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of -49.02% and 45.56%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Will Definitive Healthcare Corp. (DH) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Definitive Healthcare Corp. (DH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Is a Beat Likely for Cardinal Health (CAH) in Q4 Earnings?
by Zacks Equity Research
Cardinal Health's (CAH) fiscal fourth-quarter 2023 results are expected to reflect solid performance in the Pharmaceutical segment.
Computer Programs and Systems (CPSI) Lags Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Computer Programs and Systems (CPSI) delivered earnings and revenue surprises of -33.33% and 1.61%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
SOPHiA GENETICS SA (SOPH) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
SOPHiA GENETICS SA (SOPH) delivered earnings and revenue surprises of -13.79% and 0.32%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Augmedix, Inc. (AUGX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Augmedix, Inc. (AUGX) delivered earnings and revenue surprises of 7.69% and 3.55%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Fulgent Genetics, Inc. (FLGT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Fulgent Genetics, Inc. (FLGT) delivered earnings and revenue surprises of 75.76% and 8.25%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Zacks Industry Outlook Highlights Definitive Healthcare, Clover Health and Augmedix
by Zacks Equity Research
Healthcare, Clover Health and Augmedix are part of the Zacks Industry Outlook article.
3 Medical Info Systems Stocks to Consider From a Prospering Industry
by Urmimala Biswas
Zacks Medical Info Systems industry stocks like Definitive Healthcare (DH), Clover Health Investments (CLOV) and Augmedix (AUGX) are expected to gain from new normal trends.
Definitive Healthcare Corp. (DH) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Definitive Healthcare Corp. (DH) delivered earnings and revenue surprises of 20% and 2.95%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Outset Medical, Inc. (OM) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Outset Medical, Inc. (OM) delivered earnings and revenue surprises of -4.35% and 6.25%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Will Tabula Rasa Healthcare (TRHC) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Tabula Rasa Healthcare (TRHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Definitive Healthcare Corp. (DH) Reports Next Week: What You Should Expect
by Zacks Equity Research
Definitive Healthcare Corp. (DH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks.com featured highlights include AngioDynamics, Definitive Healthcare, Casella Waste Systems and Enviva
by Zacks Equity Research
AngioDynamics, Definitive Healthcare, Casella Waste Systems and Enviva are part of the Zacks Screen of the Week article.
4 Toxic Stocks That Are Detrimental to Your Portfolio's Health
by Lavina Shahu
Accurately identifying toxic stocks and getting rid of them at the right time can protect your portfolio. You should sell ANGO, DH, CWST and EVA.
Zacks.com featured highlights CoStar, Definitive Healthcare, Montauk Renewables and Westrock Coffee
by Zacks Equity Research
CoStar, Definitive Healthcare, Montauk Renewables and Westrock Coffee have been highlighted in this Screen of The Week article.